ACQUISITION-RELATED CHARGES (GAINS), IMPAIRMENT AND OTHER - DepoCyte Discontinuation (Details) - DepoCyte - USD ($) $ in Millions |
1 Months Ended | 12 Months Ended |
---|---|---|
Nov. 30, 2019 |
Dec. 31, 2020 |
|
Business Acquisition [Line Items] | ||
Payments for settlement | $ 5.3 | |
Non-recurring charge related to discontinuation | $ 0.2 |
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
X | ||||||||||
- Definition Amount of tax expense (benefit) on gain (loss) not previously recognized resulting from the disposal of a discontinued operation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The amount of cash paid for the settlement of litigation or for other legal issues during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Details
|